Amgen patent expiration
1. Sensipar patent expiration
SENSIPAR's oppositions filed in EPO
SENSIPAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6211244 | AMGEN | Calcium receptor-active compounds |
Oct, 2015
(8 years ago) | |
| US6313146 | AMGEN | Calcium receptor-active molecules |
Dec, 2016
(7 years ago) | |
| US6031003 | AMGEN | Calcium receptor-active molecules |
Dec, 2016
(7 years ago) | |
| US6011068 | AMGEN | Calcium receptor-active molecules |
Mar, 2018
(6 years ago) | |
| US9375405 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(2 years from now) | |
| US7829595 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-101) | Feb 25, 2014 |
| New Indication(I-634) | Feb 25, 2014 |
| Orphan Drug Exclusivity(ODE-8) | Feb 25, 2018 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2018 |
| M(M-200) | May 23, 2020 |
| Orphan Drug Exclusivity(ODE-78) | Nov 21, 2021 |
Drugs and Companies using CINACALCET HYDROCHLORIDE ingredient
Market Authorisation Date: 08 March, 2004
Treatment: Method of decreasing parathyroid hormone level; Method of treating hyperparathyroidism; Method of treating hypercalcemia
Dosage: TABLET
How can I launch a generic of SENSIPAR before it's drug patent expiration?
More Information on Dosage
SENSIPAR family patents
